{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:17:05Z","timestamp":1793848625601,"version":"4.6.1"},"reference-count":15,"publisher":"Wiley","issue":"11-12","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":3497,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[1998,12]]},"abstract":"<jats:p><jats:bold>Summary.<\/jats:bold>The efficacy and safety of two dosages of itraconazole in the treatment of tinea corporis or cruris were compared in a multicentre, randomized, double\u2010blind, parallel\u2010group trial. Fifty\u2010four patients received itraconazole 100 mg daily for 2 weeks and 60 received itraconazole 200 mg daily for 1 week. After a 6\u2010week follow\u2010up period, mycological cure was achieved in 70% of patients in the 100 mg\/2 weeks group and in 60% of those in the 200 mg\/1 week group (not significantly equivalent); in the worst\u2010case and intention\u2010to\u2010treat analyses, mycological cure rates (45\u201349%) were borderline equivalent at the end of follow\u2010up. Clinical response was seen in 80% of evaluable patients in the 100 mg\/2 weeks group and in 73% in the 200 mg\/1 week group at the end of follow\u2010up (borderline equivalent). Similar results were found in the intention\u2010to\u2010treat analysis. The tolerability ratings for the two regimens were significantly equivalent. Thirteen patients (24%) in the 100 mg\/2 weeks group but only nine (15%) in the 200 mg\/1 week group reported adverse events during treatment. Two patients in the 200 mg\/1 week group stopped treatment because of adverse events. No clinically significant changes were seen in laboratory parameters in either treatment group. This trial showed that itraconazole 200 mg for 1 week is similarly effective, equally well tolerated and at least as safe as the established regimen of itraconazole 100 mg for 2 weeks in the treatment of tinea corporis or cruris.<\/jats:p><jats:p><jats:bold>Zusammenfassung.<\/jats:bold>Wirksamkeit und Sicherheit von zwei Itraconazol\u2010Dosierungen bei der Behandlung von Tinea corporis oder cruris wurden in einer randomisierten, doppelblinden Multicentre\u2010Parallelgruppenstudie verglichen. Vierundf\u00fcnfzig Patienten wurden 2 Wochen lang mit 100 mg Itraconazol t\u00e4glich behandelt, w\u00e4hrend 60 Patienten 1 Woche lang 200 mg ftraconazol t\u00e4glich erhielten. Bei der Nachuntersuchung nach 6 Wochen war bei 70% der mit 100 mg\/2 Wochen behandelten Patienten und bei 60% der mit 200 mg\/1 Woche behandelten Patienten eine mykologische Heilung festzustellen (nicht signifikant \u00e4quivalent). In der Worst\u2010case und Intention\u2010to\u2010treat Analyse waren die mykologischen Heilungsergebnisse (45\u201349%) bei der Nachuntersuchung grenzwertig \u00e4quivalent. Bei der Nachuntersuchung wurde ein klinischer Respons bei 80% der evaluierbaren Patienten in der Gruppe mit 100 mg\/2 Wochen und bei 73% in der Gruppe mit 200 mg\/1 Woche beobachtet (grenzwertig \u00e4quivalent). Die Intention\u2010to\u2010treat Analyse f\u00fchrte zu \u00e4hnlichen Ergebnissen. Die Vertr\u00e4glichkeitsbewertung war bei beiden Therapien signifikant \u00e4quivalent. Bei 13 Patienten (24%) in der 100 mg\/2 Wochen Gruppe, aber bei nur neun Patienten (15%) in der 200 mg\/1 Woche\u2010Gruppe traten w\u00e4hrend der Behandlung Nebenwirkungen auf. Zwei Patienten in der 200 mg\/1 Woche Gruppe brachen die Behandlung aufgrund von Nebenwirkungen ab. In keiner der Behandlungsgruppen traten klinisch signifikante \u00c4nderungen der Laborbefunde auf. Diese Studie ergab, daR Itraconazol in einer Dosierung von 200 mg fur 1 Wochc dhnlich wirksam, gleich gut vertr\u00e4glich und mindcstens ebenso sicher bei der Behandlung dei Tinea corporis oder cruris ist wie die \u00fcbliche Therapie von 100 mg Itraconazol f\u00fcr 2 Wochen.<\/jats:p>","DOI":"10.1111\/j.1439-0507.1998.tb00714.x","type":"journal-article","created":{"date-parts":[[2010,7,25]],"date-time":"2010-07-25T02:44:17Z","timestamp":1280025857000},"page":"509-514","source":"Crossref","is-referenced-by-count":21,"title":["Itraconazole in the treatment of tinea corporis and tinea cruris: comparison of two treatment schedules: Itraconazol bei der Behandlung der Tinea corporis und Tinea cruris: Vergleich zweier Behandlungsschemata"],"prefix":"10.1111","volume":"41","author":[{"given":"W.","family":"Boonk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"de Geer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"de Kreek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Remme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"van Huystee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/00362178485380191"},{"key":"e_1_2_1_3_2","volume-title":"Dermatophytes: Their Recognition and Identification","author":"Rebell G.","year":"1970"},{"key":"e_1_2_1_4_2","first-page":"274","volume-title":"Harrison's Principles of Internal Medicine","author":"Swerlick R. A.","year":"1994"},{"key":"e_1_2_1_5_2","first-page":"1127","volume-title":"Textbook of Dermatology","author":"Hay R. J.","year":"1992"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.283.6295.825"},{"issue":"2","key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1439-0507.1989.tb02312.x","article-title":"Safety aspects of kctoconazole, the most commonly used systemic antifungal.","volume":"32","author":"Cauwenbergh G.","year":"1989","journal-title":"Mycoses"},{"key":"e_1_2_1_8_2","first-page":"118","article-title":"Management of fungal skin infections with 15 days itraconazole treatment: a worldwide review","volume":"44","author":"Doncker P.","year":"1990","journal-title":"Br. J. Clin. Pract"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/9.Supplement_1.S15"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1989.tb02290.x"},{"key":"e_1_2_1_11_2","first-page":"177","volume-title":"Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents.","author":"Cutsem J.","year":"1987"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.430080136"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/9.Supplement_1.S104"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(88)70037-7"},{"key":"e_1_2_1_15_2","first-page":"814","article-title":"Safety aspects of itraconazole therapy in vaginal candidosis, dermatomycosis and onychomycosis: a review","volume":"49","author":"Beule K.","year":"1991","journal-title":"Curr. Ther Res."},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000246883"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.1998.tb00714.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1439-0507.1998.tb00714.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T18:21:00Z","timestamp":1711650060000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.1998.tb00714.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,12]]},"references-count":15,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[1998,12]]}},"alternative-id":["10.1111\/j.1439-0507.1998.tb00714.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.1998.tb00714.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,12]]}}}